TCP
ADVM

Tourbillon Capital Partners’s Adverum Biotechnologies ADVM Stock Holding History

Tourbillon Capital Partners’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-53,000
Closed -$17.9M – 101
2015
Q1 		$21.5M Buy
53,000
+20,000
+61% +$8.45M 0.55% 47
2014
Q4 		$17.8M Buy
33,000
+3,000
+10% +$1.16M 0.48% 59
2014
Q3 		$10.3M Buy
+30,000
New +$8.93M 0.37% 59

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Tourbillon Capital Partners's ADVM Position: Q2 2015 in Review

Tourbillon Capital Partners sold out of Adverum Biotechnologies (ADVM) in Q2 2015, closing a stake of 53,000 shares — an estimated $17.9M sold.

Tourbillon Capital Partners first reported a position in ADVM in Q3 2014 and held it in 3 quarters. The position peaked at $21.5M in Q1 2015. 96 funds tracked by Wall St. Rank hold ADVM as of Q2 2015.

  • Tourbillon Capital Partners reported no remaining Adverum Biotechnologies position as of Q2 2015 after selling out during the quarter.
  • Tourbillon Capital Partners sold 53,000 Adverum Biotechnologies shares in Q2 2015, an estimated $17.9M.
  • Tourbillon Capital Partners first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 3 quarters.
  • Tourbillon Capital Partners's Adverum Biotechnologies position peaked at $21.5M in Q1 2015.
  • 96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2015.

Based on Tourbillon Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.